Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

Summary

The purpose of this proof of concept study was to determine whether CMK389 displays the safety and efficacy profile to support further development in chronic pulmonary sarcoidosis.

Timeline

Start

2020-09-23

Primary completion

2023-09-19

Completion

2023-12-12

Outcome

Missed primary endpoint

registry analysis (other test); CMK389 10 mg/kg i.v. vs Placebo i.v.; p = 0.1804; Posterior estimate treatment difference -1.49 (80% CI -3.56 to 0.60); Bayesian analysis NCT04064242 ↗

Drugs

Indications